Real-World Effectiveness of Risankizumab for Moderate-to-Severe Plaque Psoriasis by Sub-populations: Interim Analysis from VALUE at 37 Months.

Authors

Diamant Thaçi, Franca Wiemers, Charles W Lynde, Mamitaro Ohtsuki, Luca Bianchi, Anne-Claire Fougerousse, Francisco Javier Garcia-Latasa de Aranibar, Simina Stefanescu, Spyridon Gkalpakiotis, Paul-Gunther Sator, Julia-Tatjana Maul, Andrea Szegedi, Paula C Luna, Lynda Spelman, Simone Rubant, Tshepiso Madihlaba, Hongwei Wang, Doug Ashley, Kim A Papp

Published in

Dermatology and therapy. Nov 06, 2026. Epub Nov 06, 2026.

Abstract

This 37-month interim analysis provides an updated assessment of the overall effectiveness of risankizumab (RZB) compared with other approved biologics (OtherBios) for the treatment of psoriasis and examines RZB's effectiveness across different patient sub-populations.
The proportions of patients achieving ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90), PASI 100, PASI ≤ 1, and Dermatology Life Quality Index of 0 or 1 (DLQI 0/1), at 37 months are reported. Effectiveness was assessed in biologic-naive (bio-naive) patients, bio-experienced (bio-exp) patients, patients with high-impact area (HIA) involvement, and patients stratified by body surface area (BSA). Results are reported using modified nonresponder imputation, in which switching or discontinuing the initiated biologic due to ineffectiveness or intolerability was considered a treatment failure for subsequent visits. Propensity score matching (PSM) was employed to account for baseline characteristics imbalances. Nominal P values are reported.
Overall, 1850 patients received RZB, and 927 patients received OtherBios. The mean (SD) baseline PASI was 14.9 (9.0) and 14.0 (9.1) in the RZB and OtherBios group, respectively. At 37 months, PASI 90 (RZB versus OtherBios) was achieved by 72.1% versus 52.3% of all patients, 81.8% versus 56.5% of bio-naive patients, 62.0% versus 45.6% of bio-exp patients, 68.3% versus 42.7% of patients with BSA < 10%, 73.9% versus 57.9% of patients with BSA ≥ 10%, 72.1% versus 53.0% of patients with HIA involvement, 67.8% versus 42.9% of patients with HIA involvement and BSA < 10%, and 73.9% versus 59.0% of patients with HIA involvement and BSA ≥ 10% (all nominal P < 0.0001). Similar patterns were observed for PASI 100, PASI ≤ 1, and DLQI 0/1. No new safety signals were identified. Results were similar in the PSM population.
RZB demonstrated greater effectiveness, durability of response, and quality of life across patient sub-populations compared with OtherBios in this 37-month interim analysis.
gov Identifier: NCT03982394.

PMID:
42993474
Bibliographic data and abstract were imported from PubMed on 07 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.